BRAF gene mutations had initially been described in 13% of wild-type GIST [10], although recently they have also been reported in 2% of GIST carrying activating KIT and PDGFR-α mutations and conferring a worse prognosis and resistance to imatinib treatment [11]. The gene discussed is KIT; the disease is gastrointestinal stromal tumor.